Definium Therapeutics, Inc. (DFTX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD).
Is Definium Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of October 28, 2026, Definium Therapeutics, Inc. (DFTX) trades at $35.68 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: there is not enough data to compare it with.
Kaplio overview: Definium Therapeutics, Inc.
Market cap $5B · 52 weeks $11 – $48 (21 % below the high) · P/E no earnings · Dividend none · Next earnings November 5, 2026 · expected EPS $-0.56 · Closing price, Oct 28 · accounts published Aug 6.
- Balance sheet: Safe zone (solid).
- Earnings: 2 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: there is not enough data to compare it with.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 7.7×, fails.
- Cash Runway 38 meses, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $1.47, info.
Against its peers (reference peers) — Definium Therapeutics, Inc.: P/E —; EV/EBITDA —; ROIC -23.8 %; $4.8B. PTC Therapeutics, Inc. (P/E —; EV/EBITDA 27.8×; ROIC 2.6 %; $5.3B), Arcutis Biotherapeutics, Inc. (P/E 152×; EV/EBITDA 92.9×; ROIC 9.9 %; $4.0B), Ligand Pharmaceuticals Incorporated (P/E 34.1×; EV/EBITDA 23.1×; ROIC 3.9 %; $6.4B).
Profitability
| Return on Equity | -85.23% |
| Return on Invested Capital | -23.81% |
| Return on Assets | -31.79% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 6.95 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 4.52 |
Price Performance
| 1 month | -0.29% |
| 3 months | -12.45% |
| Year-to-date | +184.54% |
| 1 year | +195.12% |
| 3 years | +1376.74% |
| 5 years | +0.79% |
Related companies: AXSM · PRAX · VRTX · 0QZU.L · 0R2M.L · MRNA · REGN · ARGX
Explore sector: Healthcare · Biotechnology
More sections of DFTX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks